1233339-22-4

Usage

Uses

Used in Anticancer Applications:
AZ20 is used as an antitumor agent for its potent and selective inhibition of ATR kinase, which plays a crucial role in DNA damage response and cell cycle regulation. This selective inhibition has shown in vivo antitumor activity, making AZ20 a promising candidate for cancer treatment.
Used in Combination Therapy:
AZ20 is used in combination therapy with gemcitabine for synergistic inhibition of tumor cell growth and initiation of cell death in pancreatic cancer cell lines. This combination therapy enhances the efficacy of gemcitabine and may improve treatment outcomes for pancreatic cancer patients.
Used in Pharmaceutical Research:
AZ20 is used as a research tool for studying the role of ATR kinase in various cellular processes, including DNA damage response and cell cycle regulation. Its potent and selective inhibition of ATR kinase makes it a valuable compound for investigating the molecular mechanisms underlying cancer development and progression, as well as for identifying potential therapeutic targets for cancer treatment.

References

1) Foote?et al.?(2013)?Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy In Vivo Antitumor Activity; J. Med. Chem.?56?2125 2) Liu?et al.?(2017)?Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cell lines through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine; Oncol. Rep.?37?3377

Upstream product

• 1233339-68-8 (3R)-4-[2-chloro-6-(1-methanesulfonylcyclopropyl)pyrimidin-4-yl]-3-methylmorpholine 
• 94170-66-8 4-chloromethyl-2,6-dichloro-pyrimidine 
• 74572-04-6 (3R)-3-methylmorpholine 
• 1233339-73-5 (R)-4-(2-chloro-6-(methylsulfonylmethyl)pyrimidin-4-yl)-3-methylmorpholine 
• 1233339-72-4 (3R)-4-[2-chloro-6-(iodomethyl)pyrimidin-4-yl]-3-methylmorpholine 
• 1233339-70-2 [2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl]methanol 
• 1233339-69-9 methyl 2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidine-4-carboxylate 
• 6299-85-0 2,6-dichloropyrimidine-4-carboxylic acid methyl ester 
• 1233339-71-3 [2-chloro-6-[(3R)-3-methylmorpholin-4-yl]pyrimidin-4-yl]methyl methanesulfonate 
• 220465-43-0 indole-4-boronic acid 

Relevant academic research and scientific papers

Efficient Syntheses of Diverse, Medicinally Relevant Targets Planned by Computer and Executed in the Laboratory

The Chematica program was used to autonomously design synthetic pathways to eight structurally diverse targets, including seven commercially valuable bioactive substances and one natural product. All of these computer-planned routes were successfully executed in the laboratory and offer significant yield improvements and cost savings over previous approaches, provide alternatives to patented routes, or produce targets that were not synthesized previously. Although computers have demonstrated the ability to challenge humans in various games of strategy, their use in the automated planning of organic syntheses remains unprecedented. As a result of the impact that such a tool could have on the synthetic community, the past half century has seen numerous attempts to create in silico chemical intelligence. However, there has not been a successful demonstration of a synthetic route designed by machine and then executed in the laboratory. Here, we describe an experiment where the software program Chematica designed syntheses leading to eight commercially valuable and/or medicinally relevant targets; in each case tested, Chematica significantly improved on previous approaches or identified efficient routes to targets for which previous synthetic attempts had failed. These results indicate that now and in the future, chemists can finally benefit from having an “in silico colleague” that constantly learns, never forgets, and will never retire. Multistep synthetic routes to eight structurally diverse and medicinally relevant targets were planned autonomously by the Chematica computer program, which combines expert chemical knowledge with network-search and artificial-intelligence algorithms. All of the proposed syntheses were successfully executed in the laboratory and offer substantial yield improvements and cost savings over previous approaches or provide the first documented route to a given target. These results provide the long-awaited validation of a computer program in practically relevant synthetic design.

Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl) cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity

ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways. We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines that show potent and selective ATR inhibition. Optimization from a high quality screening hit within tight SAR space led to compound 6 (AZ20) which inhibits ATR immunoprecipitated from HeLa nuclear extracts with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM. Compound 6 potently inhibits the growth of LoVo colorectal adenocarcinoma tumor cells in vitro and has high free exposure in mouse following moderate oral doses. At well tolerated doses 6 leads to significant growth inhibition of LoVo xenografts grown in nude mice. Compound 6 is a useful compound to explore ATR pharmacology in vivo.

PYRIMIDINE INDOLE DERIVATIVES FOR TREATING CANCER

There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly for treating cancer.